vildagliptin
Small moleculeexperimental
Vildagliptin, sold under the brand name Galvus among others, is an oral anti-hyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. — Wikipedia
Clinical trial activity
180 trials · 108 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
88
Phase 3
81
Phase 4
59
Earliest trial started Sep 1, 2003 (NCT00099957)
Timeline
Indications
Approved for
Studied for
- Aged · Phase 4
- Anesthesia · Phase 2/Phase 3
- Bone Diseases, Metabolic · Phase 4
- Cognitive Dysfunction · Phase 4
- Coronary Artery Disease · Phase 4
- Diabetes Mellitus, Type 1 · Phase 3
- Diabetes Mellitus, Type 2 · Phase 4
- Diagnostic Self Evaluation · Phase 1
- Dyslipidemias · Phase 2
- Endothelial Cells · Phase 4
- Exercise · Phase 4
- Fasting · Phase 1
- Foot Ulcer · Phase 4
- Glucose Intolerance · Phase 2
- Healthy Volunteers · Phase 3
- Heart Failure · Phase 4
- Hypertension · Phase 4
- Hypoglycemia · Phase 4
- Hypoglycemic Agents · Phase 4
- Inflammation · Phase 4
- Insulin Resistance · Phase 3
- Kidney Failure, Chronic · Phase 1/Phase 2
- Kidney Transplantation · Phase 3
- Major Depressive Disorder · Phase 1/Phase 2
- Menopause · Phase 4
- Metabolic Syndrome · Phase 4
- Myocardial Ischemia · Phase 4
- Obesity · Phase 4
- Osteoporosis · Phase 4
- Oxidative Stress · Phase 4
- Polycystic Ovary Syndrome · Phase 2/Phase 3
- Prediabetic State · Phase 3
- Proteinuria · Phase 4
- Renal Insufficiency · Phase 4
- Schizophrenia · Phase 2
- Vascular Diseases · Phase 3
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2- Mol. weight
- 303.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaVildagliptin ↗
- ChEMBLCHEMBL142703 ↗
Also known as
- 1-(((3-hydroxy-1-adamantyl)amino)acetyl)-2-cyanopyrrolidine
- (2s)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
- equa
- equa
- galvus
- galvus
- galvus
- galvus
- galvus
- galvus
- haaa-2-cyanopyrrolidine
- jalra
- jalra
- jalra
- laf237
- laf237
- laf237
- laf 237
- laf-237
- laf-237
- laf-237
- nvp-laf237
- nvp-laf237
- nvp-laf237
- nvp-laf237
- nvp-laf237
- nvp-laf-237
- nvp-laf-237
- vidagliptin
- vidagliptin
- vildagliptin
- vildagliptin
- vildagliptin
- vildagliptin
- vildagliptin
- vildagliptin
- vildagliptin
- vildagliptin
- vildagliptin
- vildagliptin hcl
- vildagliptin hydrochloride
- vildagliptin / metformin hydrochloride
- xiliarx
- xiliarx
- xiliarx
- xiliarx
- xiliarx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06951334 | N/A | Jun 1, 2025 | Sun Yat-Sen University |
| NCT06851962 | Phase 4 | Apr 30, 2025 | University of Valencia |
| NCT06889909 | N/A | Dec 15, 2024 | Post-Graduate Medical Institute, Lahore |
| NCT06913101 | N/A | Nov 15, 2024 | PNS Hafeez - Naval Hospital |
| NCT06248801 | Phase 1 | Sep 5, 2024 | Bio-innova Co., Ltd |
| NCT06244407 | Phase 1 | May 23, 2024 | Mahidol University |
| NCT06142656 | Phase 2/Phase 3 (Phase 3) | Nov 25, 2023 | October 6 University |
| NCT06313008 | N/A | Aug 10, 2023 | Damanhour University, Tanta University |
| NCT07077525 | Phase 4 | Jun 1, 2023 | Al Azhar University, General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT06103747 | Phase 1 | Feb 21, 2023 | — |
| NCT06068686 | N/A | Oct 1, 2022 | Damanhour University |
| NCT05366868 | Phase 4 | May 26, 2022 | National Center for Global Health and Medicine, Sumitomo |
| NCT06073600 | Phase 1 | May 20, 2022 | — |
| NCT05102149 | Phase 3 | Dec 31, 2021 | PegBio Co., Ltd., Peking University |
| NCT04841096 | Phase 3 | Jun 30, 2021 | Centro de Investigación Médica Aguascalientes (Red OSMO), Laboratorios Silanes S.A. de C.V., Mérida Investigación Clínica, Oncológico Potosino (Red OSMO) |
| NCT04761861 | Phase 2 | Feb 16, 2021 | Sadat City University |
| NCT05359432 | Phase 4 | Jul 1, 2020 | Dow University of Health Sciences, Getz Pharma |
| NCT04410341 | Phase 1/Phase 2 (Phase 2) | May 1, 2020 | Sadat City University |
| NCT04916093 | Phase 4 | Dec 20, 2019 | Beni Suef University, Minia University |
| NCT04485845 | Phase 4 | Nov 1, 2019 | Cairo University |
Showing 20 of 180 trials
Page 1 / 9
Organizations
Research & Development (108)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 103 | 94 | 5 | 2003 |
| Lund University | Academic/Hospital | 4 | 4 | 1 | 2010 |
| AET Laboratories Private Limited | For profit | 3 | 3 | 1 | 2014 |
| Damanhour University | Academic/Hospital | 3 | 3 | 2 | 2018 |
| Sanofi | For profit | 3 | 3 | 1 | 2014 |
| Seoul National University | Academic/Hospital | 3 | 3 | 2 | 2008 |
| Tanta University | Academic/Hospital | 3 | 1 | 3 | 2018 |
| Cairo University | Academic/Hospital | 2 | 1 | 1 | 2017 |
| Government of Egypt | Government | 2 | 0 | 1 | 2017 |
| Hanmi Pharmaceutical | For profit | 2 | 2 | 1 | 2018 |
| Korea University | Academic/Hospital | 2 | 1 | 1 | 2009 |
| Mayo Clinic | Academic/Hospital | 2 | 1 | 1 | 2005 |
| Merck | For profit | 2 | 2 | 1 | 2011 |
| Peking University | Academic/Hospital | 2 | 1 | 2 | 2016 |
| Sadat City University | Academic/Hospital | 2 | 2 | 1 | 2020 |
| University of Campania Luigi Vanvitelli | Academic/Hospital | 2 | 2 | 1 | 2005 |
| University of Copenhagen | Academic/Hospital | 2 | 2 | 1 | 2009 |
| University of Picardie Jules Verne | Academic/Hospital | 2 | 0 | 2 | 2014 |
| University of Strasbourg | Academic/Hospital | 2 | 1 | 2 | 2014 |
| University of Toulouse | Academic/Hospital | 2 | 1 | 2 | 2010 |
108 organizations
Page 1 / 6